Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

Author： Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.5, 2011-05, pp. : 951-960

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload

By  

Acta Haematologica, Vol. 138, Iss. 2, 2017-09 ,pp. : 119-128

Karger

Access to resources Recommend Favorite

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes

By  

Oncology Research and Treatment, Vol. 23, Iss. 1, 2000-03 ,pp. : 12-16

Karger

Access to resources Recommend Favorite

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia

By Ben-Hamadi R.   Duh M. S.   Aggarwal J.   Henckler A.   Mckenzie R. S.   Tak Piech C.  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1677-1682

Informa Healthcare

Access to resources Recommend Favorite

Chemotherapy-induced anemia: the story of darbepoetin alfa

By Vansteenkiste Johan   Wauters Isabelle   Elliott Steven   Glaspy John   Hedenus Michael  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 325-337

Informa Healthcare

Access to resources Recommend Favorite